Q-omics provides the consensus-scored HEPACAM2 profile across patient tissues and cancer cell-line models. HEPACAM2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HEPACAM2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, HEPACAM2 RNA expression shows 16,096 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where HEPACAM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEPACAM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEPACAM2 survival associations across molecular data types. HEPACAM2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEPACAM2 RNA expression–survival associations across cancer types. High HEPACAM2 expression shows unfavorable associations in UCEC, KIRP, ESCA and UVM, but favorable associations in COAD and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for HEPACAM2 RNA expression.
This table summarizes HEPACAM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HEPACAM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEPACAM2 shows lower tumor expression in KIRC, KIRP, COAD, HNSC and THCA and higher tumor expression in KICH. The KIRC box plot shows higher HEPACAM2 RNA expression in normal versus tumor tissue (log2 FC = −4.593, t-test p < 0.001).
This table shows molecular features associated with HEPACAM2 in patient tissues and cancer cell lines. In patient samples, HEPACAM2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HEPACAM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
